Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Leukoreduced red blood cells are a type of packed red blood cell product from which the vast majority of white blood cells (leukocytes) have been removed, typically by filtration or apheresis. This process retains at least 85% of the original red cell content and reduces residual white cell count to less than 5 x 10^6 per unit in the United States (1 x 10^6 in Europe)[5][8]. The primary indications for transfusing leukoreduced RBCs include prevention of alloimmunization to foreign HLA antigens, reduction in febrile nonhemolytic transfusion reactions, and decreased risk of cytomegalovirus (CMV) transmission—especially important for immunocompromised or pregnant patients[1][2][4][6]. Leukoreduction may also help reduce other complications such as platelet refractoriness and possibly transfusion-related immunomodulation. However, it does not prevent all risks; for example, irradiation is still required to prevent transfusion-associated graft-versus-host disease[6][10]. Leukoreduction is now standard practice in many countries.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on leukoreduced red blood cells.